ASPREE-D: Aspirin for the prevention of depression in the elderly Berk, Michael, Woods, R.L., Nelson, M.R., Shah, R.C., Reid, C.M., Storey, E., Fitzgerald, S.M., Lockery, J.E., Wolfe, R., Mohebbi, M., Murray, A.M., Kirpach, B., Grimm, R. and McNeil, J.J. 2016, ASPREE-D: Aspirin for the prevention of depression in the elderly, International psychogeriatrics, vol. 28, no. 10, pp. 1741-1748, doi: 10.1017/S104161021600079X. Attached Files Name Description MIMEType Size Downloads Title ASPREE-D: Aspirin for the prevention of depression in the elderly Author(s) Berk, Michael orcid.org/0000-0002-5554-6946 Woods, R.L. Nelson, M.R. Shah, R.C. Reid, C.M. Storey, E. Fitzgerald, S.M. Lockery, J.E. Wolfe, R. Mohebbi, M. orcid.org/0000-0001-9713-7211 Murray, A.M. Kirpach, B. Grimm, R. McNeil, J.J. Journal name International psychogeriatrics Volume number 28 Issue number 10 Start page 1741 End page 1748 Total pages 8 Publisher Cambridge University Press Place of publication Cambridge, Eng. Publication date 2016-10 ISSN 1741-203X Keyword(s) antidepressants aspirin biomarkers depression immunology inflammation prevention risk Social Sciences Science & Technology Life Sciences & Biomedicine Psychology, Clinical Geriatrics & Gerontology Gerontology Psychiatry Psychology C-REACTIVE PROTEIN SCALE CES-D ACETYLSALICYLIC-ACID MAJOR DEPRESSION INFLAMMATORY MARKERS DISORDERS AUGMENTATION METAANALYSIS ASSOCIATION FLUOXETINE Summary BACKGROUND: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention. METHOD: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression. RESULTS: This paper presents the rationale for the study and presents a summary of the study design. CONCLUSIONS: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression. Language eng DOI 10.1017/S104161021600079X Field of Research 110319 Psychiatry (incl Psychotherapy) Socio Economic Objective 920410 Mental Health HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2016, International Psychogeriatric Association Persistent URL http://hdl.handle.net/10536/DRO/DU:30090270 Document type: Journal Article Collections: Faculty of Health School of Medicine Centre for Quality and Patient Safety Research Related Links Link Description Connect to published version Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 16 Dec 2016, 13:32:00 EST Sat, 17 Dec 2016, 04:00:40 EST Fri, 03 Feb 2017, 05:04:34 EST Tue, 14 Feb 2017, 10:09:12 EST Tue, 14 Feb 2017, 10:12:23 EST Filtered Full Citation counts:   Cited 10 times in TR Web of Science Cited 10 times in Scopus Search Google Scholar Access Statistics: 456 Abstract Views, 1 File Downloads  -  Detailed Statistics Created: Fri, 16 Dec 2016, 13:32:00 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.